O TYM ODCINKU
Press Releases are an increasingly common method to learn about new/upcoming data. What can clinicians learn (and what can't we learn) from these? We read through two examples for just this purpose.
Example 1: https://www.amgen.com/newsroom/press-releases/2026/09/imdelltra-in-combination-with-imfinzi-demonstrated-landmark-improvement-in-overall-survival-in-first-line-extensive-stage-small-cell-lung-cancer
Example 2: https://aptevotherapeutics.gcs-web.com/news-releases/news-release-details/aptevo-reports-93-clinical-benefit-rate-mipletamig-triplet
Possible Help with Drug Shortages: https://www.angelsforchange.org
Download the Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm
Example 1: https://www.amgen.com/newsroom/press-releases/2026/09/imdelltra-in-combination-with-imfinzi-demonstrated-landmark-improvement-in-overall-survival-in-first-line-extensive-stage-small-cell-lung-cancer
Example 2: https://aptevotherapeutics.gcs-web.com/news-releases/news-release-details/aptevo-reports-93-clinical-benefit-rate-mipletamig-triplet
Possible Help with Drug Shortages: https://www.angelsforchange.org
Download the Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm
Język angielski
Stany Zjednoczone
TRANSKRYPCJA 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
WYSZUKAJ MINIONE ODCINKI
Wyszukaj minione odcinki OncoPharm.
INNE ODCINKI W TYM PODCASCIE
This week's pod has everything:
1. DDI information and dosing for daraxonrasib, now FDA approved and commercially available for pancreatic cancer
2. A new standard of care (?) in HER(+) gastric cancers, and more nuance on HER2 positivity. And lots of diarrhea.
3. The largest RCT in primary CNS lym…
PARADIGM is finally published, so we have more details from this study presented at ASH about HMA/Ven vs. Intensive Chemo if fit patients with AML.
Daraxonrasib looks like a promising drug for RAS-mutant NSCLC, too.
Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-…
CELMoDs are here, but are they here to stay?
CELMoD/IMiD review article: https://doi.org/10.1080/17474086.2024.2382897
Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm
Overview of renal cell carcinoma
Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm
Zastrzeżenie: Podcast i grafika osadzone na tej stronie pochodzą z John Bossaer, który jest własnością jego właściciela i nie jest powiązany ani wspierany przez Listen Notes, Inc.
EDYTUJ
Dziękujemy za pomoc w aktualizowaniu podcastowej bazy danych.
